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Summary Since the vascular endothelium is a primary site of damage after photodynamic therapy (PDT), it
seemed likely that drugs which affect the vasculature may modify the outcome of PDT. Noradrenaline,
propranolol, hydralazine and phenoxybenzamine inhibited photodynamic damage to tumours if these drugs
were administered concurrently with HPD,2h before irradiation. This inhibition was associated with reduced
uptake of HPD into tumours. There was no inhibition if irradiation was delayed until 24h after
administration of vasoactive drug, presumably because HPD uptake continued after the drugs had ceased to
affect the vasculature. Verapamil enhanced photodynamic destruction of tumours when administered
concurrently with HPD and the enhancement was associated with increased uptake of HPD into tumours.
Verapamil neither increased uptake of HPD nor enhanced photodynamic destruction of cells in vitro. When
verapamil was administered after irradiation, regrowth of tumours was inhibited. A similar effect was
previously demonstrated with glucocorticoids. Other calcium channel blocking agents diltiazem and nifedipine
had no effect on uptake of HPD or inhibition of regrowth of tumours after PDT. Inhibition of capillary or
stromal ingrowth into tumours seems a plausible explanation of this effect of verapamil. This commonly used
drug may be useful to enhance the efficacy of PDT.
Photodynamic therapy (PDT) of malignant tumours using
haematoporphyrin derivative (HPD) depends on the selective
uptake and retention of HPD in tumours and its subsequent
activation by light (Benson, 1985; Forbes et al., 1980;
Hayata et al., 1984). Destruction of tumours is mediated
through production of toxic oxygen species by photo-
activated HPD (Lee See et al., 1984; Das et al., 1985).
The primary target of PDT may be the microvasculature
of tumours rather than the tumour cells. Studies using
radiolabelled HPD indicate that its uptake and retention are
greater in the stroma than in the tumour cells and macro-
phages in this site retain HPD longest (Bugelski et al., 1981).
Tumour blood flow, as measured with microspheres, was
reduced after PDT (Selman et al., 1984, 1985) and complete
cessation of tumour blood flow was observed in rat tumours
in observation chambers after PDT (Star et al., 1984).
Histological examination indicated that the primary site of
photodynamic damage in the normal mouse brain was the
endothelium of small vessels (Berenbaum et al., 1986). PDT
caused necrosis of L1210 solid tumours in mice, but cells
isolated from L1210 tumours after the host mice had
received HPD contained little HPD and were not killed by
irradiation in vitro (Musser & Datta-Gupta, 1984). Similarly,
viability of EMT-6 tumour cells, as measured by capacity to
form colonies in vitro, was not reduced if tumours were
removed from mice immediately after irradiation in vivo.
Viability of cells from tumours left in the mice after
irradiation decreased at the same rate as when tumours were
made anoxic (Henderson et al., 1985).
In view of these findings, it could be predicted that
vasoactive drugs may modify the outcome of PDT. The
uptake of HPD into tumours may be altered by vasodilation
or vasoconstriction altering tumour blood flow. The
destruction of tumours may also be modified if the drugs
sensitise capillaries to photodynamic destruction. The
possibility of unwanted side-effects in patients receiving both
vasoactive drugs and PDT should also be investigated.
Vasodilating drugs propranolol (a beta receptor blocking
agent), hydralazine, phenoxybenzamine (an alpha receptor
blocking agent) and the vasoconstricting agent noradrenaline
were all tested. In addition, the calcium channel blocking
agents verapamil, nifedepine and diltiazem, which also have




The assay was modified from Dougherty et al. (1983)
(Cowled & Forbes, 1985; Cowled et al., 1985a). Lewis lung
carcinoma cells, cultured in RPMI 1640 supplemented with
10% foetal calf serum (FCS), 2.3mM NaHCO3, 25mM N-2-
hydroxyethylpiperazine N'-2-ethanesulphonic acid and
0.16pgml-1 gentamicin, were harvested by treatment with
0.01% trypsin. A total of 106 cells were injected sub-
cutaneously into the back of C57B1 mice. Fresh cultures
were established every three months from stock frozen in
liquid nitrogen. After 7-10 days, tumours were 5-7mm in
diameter and were ready for treatment.
Tumour-bearing mice in groups of 10 were injected with
HPD (30mgkg-' i.p.), prepared as in Forbes et al. (1980).
Twenty-four hours later, the mice were anaesthetised with
sodium pentobarbitone (Sagatal, May and Baker Australia
Proprietary Limited, 60mgkg-1), the fur over the tumour
was shaved and the tumours were irradiated over a 1 cm
diameter spot with a light dose of 225 Jcm-2 from an
incandescent lamp (610-680nm) (Jacka & Blake, 1983). The
skin around the tumours was not shielded. Tumours were
impalpable 24h after an effective treatment and the end-
point of the assay was the number of days for five of 10
tumours to recur (TC50). There was a linear relationship
between the TC50 and both the light and HPD doses
(Cowled & Forbes, 1985). In other experiments, mice were
injected with HPD (50mgkg-1), the tumours irradiated 2h
later with 225 Jcm-2 light and TC50 determined as described
above. All experiments were repeated at least once and
means and standard deviations between groups of 10 mice
were determined. Differences between groups of mice were
analysed by unpaired t tests.
Drugs were administered either concurrently with HPD,
immediately before irradiation or 24 and 48 h after
irradiation. The drug dosages, mode of administration and
interval between drug administration and irradiation are
described in detail in the figure legends.
In vitro photocytotoxicity
Lewis lung carcinoma cells, grown and harvested as
described above, were suspended at 107ml- in RPMI 1640/
10% FCS and incubated for 1 h at 37°C with 50PCiml-1
5'Cr-sodium chromate (Amersham, Australia). After
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washing, 51Cr-labelled cells were suspended at 107ml-l in
RPMI 1640 without FCS and incubated for 1 h at 37°C with
HPD (25 igml-1) and verapamil (0-100 gml-1). The cells
were washed once, resuspended in phosphate-buffered saline
at 0.5 x 106 ml-1 and irradiated for 0-20min with red light
(8mWcm-2). Percentage "Cr release was determined
immediately after irradiation as previously described (Cowled
et al., 1985b). Background percentage 51Cr release, from
cells incubated in HPD or HPD plus verapamil but not
irradiated, was subtracted from all experimental values.
Fluorescence detection of HPD
Twenty-four hours after receiving HPD and vasoactive
drugs, the mice were killed, tumours were dissected out and
frozen sections (6pm) were examined under a Zeiss fluor-
escence microscope with excitation wavelength 420-490nm.
Fluorescence intensity was not quantitated. Uptake of HPD
in vitro was assessed by flow cytometry (Becton Dickinson
FACS analyser, excitation wavelength 485+10nm and read-
out fluorescence at 575+13nm) after incubating Lewis lung
carcinoma cells for 1h in HPD plus verapamil as above.
Cells were washed and resuspended in phosphate-buffered
saline at 2xI106ml-1 for fluorescence assays. Fluorescence
data were analysed on a Hewlett-Packard model 310
computer with Becton Dickinson 'consort 30' software
package and the mean fluorescence was calculated. Since it is
possible that HPD could be lost from the tumour cells
during disaggregation of the intact tumours, measurement of
HPD fluorescence in vivo was not attempted.
Results
Influence of vasoactive drugs administered 24h before
irradiation
Vasoactive drugs were administered i.v. concurrently with
HPD (i.p.) and the tumours irradiated 24h later. The results
are shown in Figure 1. Slight increases in TC50 observed
with noradrenaline and hydralazine were not statistically
significant. A significant (P<0.02) increase in TC50 was
observed after 0.5mgkg-1 propranolol but not after
1.0mgkg-1. Noradrenaline, propranolol and hydralazine
administered immediately before irradiation of tumours in
HPD-sensitised mice also had no effect on PDT, the TC50
remaining at 3-4 days in all cases. Drug alone, drug plus
HPD, or drug without HPD followed 5min or 24h later by
irradiation of the tumours did not affect tumours macro-
scopically. The highest doses of all the drugs tested caused
temporary drowsiness in the mice but were not fatal.
Intensity of HPD fluorescence in the tumours was not
altered when the vasoactive drugs were administered 24h
before examining fluorescence, indicating that these drugs
had no effect on HPD uptake into the tumours. This was in
agreement with the lack of influence of the drugs on PDT.
Influence of vasoactive drugs administered 2h before
irradiation
Since the half-life of the vasoactive drugs in mice could be
quite short, examination of the response of the tumours to
PDT 24h after drug administration may not reveal short-
term effects. Therefore the interval between administration
of HPD plus drug and irradiation was shortened to 2h.
Previous studies had shown 2h was the shortest interval
between HPD and irradiation of the tumours at which an
adequate response could be obtained (Cowled, 1986).
Irradiation 2h after injection of HPD (50mgkg-1)
resulted in a greater TC50 than that observed with an
interval of 24h between HPD (30mgkg-1) and light. All the
vasoactive drugs which were tested greatly inhibited the
tumour response to PDT when the interval between drug
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Figure 1 Effect of vasoactive drugs administered concurrently
with HPD 24h before irradiation. Mice with Lewis lung
carcinoma were given HPD (i.p.) plus vasoactive drugs (i.v.) and
the tumours irradiated 24h later with 225Jcm-2 red light. Each
bar represents the mean+s.d. of two experiments. A, HPD
(30mgkg-1); B, HPD plus noradrenaline (Levophed, Winthrop,
0.1 mgkg-); C, HPD plus noradrenaline (0.2mgkg-1); D, HPD
plus propranolol (Inderal, ICI Australia, 0.2mgkg-1); E, HPD
plus propranolol (0.5mgkg-1); F, HPD plus propranolol
(1.0mgkg-1); G, HPD plus hydralazine (Apresoline, Ciba-Geigy
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Figure 2 Effect of vasoactive drugs administered concurrently
with HPD 2h before irradiation. Mice with Lewis lung
carcinoma were given HPD (i.p.) plus vasoactive drugs (i.v.) and
the tumours irradiated 2h later with 225Jcm-2 red light. Each
bar represents the mean+s.d. of two experiments. A, HPD
(50mgkg-1); B, HPD plus noradrenaline (0.1 mgkg-1); C, HPD
plus noradrenaline (0.2mgkg-1); D, HPD plus hydralazine
(10mgkg-1); E, HPD plus propranolol (1 mgkg-1); F, HPD
plus a mixture of noradrenaline (0.2mgkg-1) and propranolol
(0.5mgkg-1); G, HPD plus phenoxybenzamine (Dibenyline,
Smith Kline and French Laboratories, Australia Ltd, 5mgkg-);
H, HPD plus a mixture of noradrenaline (0.2mgkg-1) and
phenoxybenzamine (1mgkg-1); I, HPD plus a mixture of nor-
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inhibitory, appearing to suppress completely the effect of
irradiation on some tumours.
Fluorescence of tumours was greatly diminished 2h after
concurrent administration of HPD (50mgkg-1) and hydral-
azine (10mlkg-1), propranolol (1mgkg-') or phenoxy-
benzamine (5mgkg-1), indicating marked inhibition of
uptake of HPD. Noradrenaline also inhibited uptake of
HPD into the tumours. Fainter fluorescence after
0.2mgkg-1 noradrenaline than O.1 mgkg- was associated
with a greater inhibition of efficacy of PDT.
Local administration of noradrenaline (200 il of
0.02mgml-1, amounting to 0.2mgkg-1 into tumours
concurrently with the administration of HPD (50mgkg-1
i.p.) 2h before irradiation, also greatly inhibited the response
to PDT. Eight out of 10 tumours were still palpable 24h
after irradiation (TC50 of <1 day compared to 8 days).
HPD fluorescence in the tumours was also greatly inhibited
by local infiltration of noradrenaline. Controls of local
noradrenaline alone or noradrenaline plus light had no
macroscopic effect on the tumours. These results would
indicate that the effect of noradrenaline on uptake of HPD
into tumours could be at least partly due to effects of
noradrenaline on the tumour blood vessels and not merely
due to systemic vasoconstriction affecting the distribution or
circulation of HPD in the mouse.
Under the conditions tested, the alpha blocker phenoxy-
benzamine did not prevent the inhibition of PDT by nor-
adrenaline, an alpha agonist (Figure 2). Indeed the inhibition
of PDT was enhanced, most tumours being macroscopically
unaffected. Phenoxybenzamine itself administered
concurrently with HPD 2h before irradiation, also inhibited
PDT (Figure 2). The inhibition of PDT by noradrenaline
was not altered by concurrent administration of the beta
blocker propranolol (Figure 2). Higher doses of propranolol
in combination with noradrenaline were fatal to the mice.
All drugs alone, drugs plus HPD (without irradiation) and
drugs plus irradiation (without HPD) had no effect on the
rate of tumour growth.
Calcium channel blockers
Verapamil (2mgkg-1) potentiated PDT when administered
concurrently with HPD 24h before irradiation (Figure 3).
No greater effect was seen using this drug at 10mgkg-'. A
marked increase in fluorescence in frozen sections 24h after
injection of verapamil (10mgkg-1) plus HPD suggested that
verapamil increased uptake or retention of HPD in the
tumours. A second calcium channel blocking agent,
nifedepine, was also tested. Nifedepine, being extremely
insoluble in aqueous solutions, was dissolved in 5% dimethyl
sulphoxide (DMSO) in saline and then injected concurrently
with HPD. Both the photodynamic effect and the uptake of
HPD, as assessed by fluorescence, were greatly inhibited.
However, 5% DMSO without nifedepine administered with
HPD also inhibited both the uptake of HPD and the
photodynamic response. The reason for this inhibition is
unclear. Thus the influence of nifedepine on PDT could not
be assessed. Diltiazem was also tested (Figure 3). In contrast
to verapamil, when diltiazem (10mgkg-1) was administered
concurrently with HPD 24h before irradiation, there was no
change in the TC50, which remained at 4 days. The fluor-
escence of HPD in tumours was similarly unaffected by
diltiazem. Controls of drugs alone, drug plus HPD or drug
plus light had no effect on the tumours.
Verapamil (2mgkg-1) administered 24 and 48h after
irradiation significantly increased the TC50 from 3.6 to 6
days. However, in contrast, neither nifedepine (2 mgkg-1,
dissolved in 5% DMSO in saline) or diltiazem (10 or
50mgkg-1) had any effect on the TC50 when administered
24 and 48 h after PDT (Figure 4). The insolubility of
nifedepine in aqueous solutions limited the doses at which it
could be tested. A control solution of 5% DMSO in saline







Figure 3 Influence of calcium channel blocking drugs
administered concurrently with HPD. Mice with Lewis lung
carcinoma were given HPD and calcium channel blocking drugs
and the tumours irradiated 24h later with 225Jcm-2 red light.
Each bar represents the mean+s.d. of two experiments. A, HPD
(30mgkg-1 i.p.); B, HPD plus verapamil (Isoptin, Knoll AG,
2mgkg- I i.p.); C, HPD plus verapamil (2mgkg 1 i.v.); D, HPD
plus verapamil (10mgkg-1 i.p.); E, HPD plus diltiazem (ICI
Australia, 10mgkg-1 i.p.). *P<0.02; **P<0.01.
rate of recurrence of the tumours. Verapamil (10mgkg-1)
administered to mice at the time of tumour transplant also
had no effect on the rate of tumour growth. The mean time
for tumours to become palpable was 7.8+1.4 days when
verapamil was administered with transplants and 7.5+1.3
days without verapamil.
Influence of verapamil on the photoactivity of HPD in vitro
Verapamil could act on PDT by affecting the supply of HPD
to tumours, or by a direct effect on tumour cells. In an
attempt to distinguish between these possibilities, the
influence of verapamil on photodynamic destruction of
tumour cells was examined in vitro. Verapamil had no effect
on 5'Cr release from HPD-sensitised Lewis lung carcinoma
cells (Figure 5). Uptake of HPD into Lewis lung carcinoma
cells was assessed by flow cytometry. The mean fluorescence
was proportional to the concentration of HPD added to the
incubation mixture (data not shown), suggesting mean fluor-
escence was a measure of intracellular HPD concentration.
Verapamil did not markedly affect the mean fluorescence of
Lewis lung carcinoma cells incubated in HPD (Figure 6),
suggesting HPD uptake was not affected by verapamil.
Neither verapamil (10-50/jigml-1) alone nor verapamil plus
light increased 51Cr release above background. Since
incubation of cells in verapamil alone at a concentration of
100 gml-l caused some release of 51Cr above background,
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Figure 4 Influence of calcium channel blocking drugs
administered 24 and 48h after PDT. Mice with Lewis lung
carcinoma were given HPD (30mgkg-' i.p.) and tumours
irradiated 24h later with 225Jcm-2 red light. The calcium
channel blocking drugs were administered i.p. 24 and 48h after
irradiation. Each bar represents the mean+s.d. of two
experiments. A, HPD and light only; B, verapamil (2mgkg-1);
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Figure 5 Influence of verapamil on PDT in vitro. 5'Cr-labelled
Lewis lung carcinoma cells were incubated for 1 h at 37°C with
HPD (25pgml-') and verapamil (l-100lgml- ) and irradiated
for 0-20min. Percentage 5"Cr was determined immediately after
irradiation. Each point represents the mean+s.d. of triplicates.
0, HPD (25 igml-1); 0, HPD plus verapamil (Opgml-1); *,
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Figure 6 Effect of verapamil on uptake of HPD in vitro. Lewis
lung carcinoma cells were incubated for 1 h at 37'C with HPD (0
or 25 ugml-1) and verapamil (0-lOOgml-1), washed and
suspended in PBS. Mean fluorescence intensity was read on a
Becton Dickinson FACS analyser. Each point represents the
mean+s.d. of triplicates. 0, no HPD; 0, HPD (25pgml-1).
Discussion
The influence on PDT of drugs affecting vasculature was
examined using a transplantable tumour model in mice.
Noradrenaline, propranolol and hydralazine inhibited PDT if
given 2h before tumours were irradiated, but had no effect
when administered with HPD 24h before irradiation. The
fluorescence of HPD in tumours was reduced 2 h after
administration of noradrenaline with HPD, but not after
24h. Phenoxybenzamine, an alpha receptor blocking agent
and the beta blocker propranolol did not block the
inhibitory effect of noradrenaline on PDT. Noradrenaline
acts mainly on alpha receptors (Weiner, 1985).
Administration of noradrenaline, hydralazine or propanolol
immediately before irradiation had no effect on the
TC50.
There is controversy as to whether blood vessels of
tumours respond to vasoactive drugs. Blood flow in rat
tumours was reduced by local administration of nor-
adrenaline (Mattsson et al., 1980) and vasoconstriction was
observed directly by microangiography (Mattsson et al.,
1981). Decreasing vascular responses to propranolol,
papaverine and dihydralazine have been observed as tumours
age (Wickersham et al., 1977; Peterson & Mattsson, 1984).
As tumours enlarge, the blood vessels become stretched and
tortuous, lose adrenergic innervation and show a relative
lack of smooth muscle (Mattsson & Peterson, 1981). The
inhibition of PDT by vasolidators administered 2h before
irradiation could be explained by dilatation of normal vessels
causing diversion of blood from tumours. Reduction of
tumour blood flow has been demonstrated after the intra-
venous doses of noradrenaline used in this study and this
effect was blocked by phenoxybenzamine (Mattsson et al.,
1978). However, since phenoxybenzamine itself inhibited
PDT, this drug could not be used to block the inhibitory
action of noradrenaline on PDT. Administration of these
drugs immediately before irradiation had no effect on the
response of the tumours to PDT, suggesting that the degree
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of vasodilation or vasoconstriction of the tumour vasculature
at the time of irradiation does not influence the outcome of
PDT.
Damage to tumours by PDT appears to be mediated by
toxic oxygen species, particularly singlet oxygen and
hydroxyl radicals (Das et al., 1985). It is possible that
vasoactive drugs alter tumour responses to PDT by altering
the oxygen tension in the tumours and hence altering the
production of toxic oxygen species. Vasoactive drugs have
been reported to alter oxygen tension (Kruuv et al., 1967).
Verapamil, a calcium channel blocking agent and vaso-
dilator, enhanced the efficacy of PDT. Enhancement of HPD
fluorescence in tumours suggested that this resulted from
increased uptake of HPD. However, since vasodilators
inhibited both uptake of HPD and the degree of photo-
dynamic damage, an effect of verapamil other than its
vasodilatory action is probably responsible. The capacity of
verapamil to affect blood flow of tumours is also
controversial. In one study, tumour blood flow was
increased by verapamil without altering blood flow in
normal tissues (Kaelin et al., 1982), but no enhancement of
tumour blood flow was detected in another study (Robinson
et al., 1985). It is of interest that verapamil increases the
number of low density lipoprotein (LDL) receptors on the
surface of cells (Stein et al., 1985), as it has been suggested
that HPD may be taken up into cells by LDL receptors
(Candide et al., 1986).
Verapamil enhances the effect of cytotoxic drugs in other
systems. Tumour cell lines, including Lewis lung carcinoma
used in this study, resistant to adriamycin and vincristine,
were made sensitive by verapamil (Tsuruo et al., 1982,
1983a,b,c). Intracellular concentrations of cytotoxic drugs
were elevated, suggesting that verapamil enhanced uptake or
inhibited transport of drugs out of cells. Our studies in vitro
did not indicate a direct action of verapamil on the tumour
cells. When Lewis lung carcinoma cells were incubated in
HPD plus verapamil, HPD fluorescence and 51Cr release
were not increased significantly.
The most important effect of verapamil in enhancing PDT
appears not to be the enhancement of uptake of HPD into
tumours, but prolongation of the tumour-free interval when
the drug is administered after irradiation. At least two
mechanisms may be suggested to explain this phenomenon:
(1) enhancement of the effect of hypoxia induced by
capillary damage after PDT and (2) inhibition of regrowth of
the tumour from surviving cells. Since virtually all non-
malignant cells appear to proliferate and differentiate in
response to appropriate growth factors, it seems likely that
capillaries and host stromal cells may only grow in
association with multiplying tumour cells if they also receive
the necessary growth factors. Verapamil could inhibit some
steps necessary for this process. High-dose cortisone, in
combination with heparin, has been shown to inhibit angio-
genesis (Folkman et al., 1983; Crum et al., 1985). Gluco-
corticoids administered after PDT also inhibit recurrence of
tumours (Cowled et al., 1985a). It is also of interest that the
effects on PDT of verapamil are not common to all calcium
channel blocking drugs and the reasons for these differences
are not known. Diltiazem, a drug with pharmacological
action similar to that of verapamil (Needleman et al., 1985),
had no effect on the uptake of HPD. Diltiazem and
nifedepine also had no effect on the rate of recurrence of
tumours after PDT.
We conclude that many vasoactive drugs may modify the
uptake of HPD, inhibiting PDT if tumours are irradiated
shortly afterwards. Verapamil acts differently, both
enhancing the uptake of HPD and acting after
photodynamic destruction to inhibit the regrowth of
tumours. Verapamil may be very useful clinically to enhance
the efficacy of PDT and experimentally to study the
regrowth of tumours after PDT.
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